Cizzle Biotechnology Holdings PLC - London-based life sciences company engaged in developing a blood test for the early detection of the different forms of lung cancer - Appoints Founder & Non-Executive Director Dawn Coverley as chief scientific officer, effective immediately. Says the new role replaces her position as a NED and accelerates its global licensing and partnership strategy to bring its non-invasive, cost effective, CIZ1B biomarker lung cancer blood test to market in 2025.

Adds that the appointment coincides with the successful completion of a technical programme to launch the most scalable version of the CIZ1B biomarker assay as an Enzyme-Linked Immunosorbent Assay for Clinical Laboratory Improvement Amendments accreditation.

Executive Chair Allan Syms says: ‘I am delighted that Dawn will be able to allocate more of her time to directly support the Company as we progress through the commercial phase and the test is rolled out to partner laboratories. As the founder of Cizzle and the world expert on the CIZ1 gene and our CIZ1B variant biomarker, Dawn will be able to take a greater role in the direction and implementation of our entire research and development programme, managing Cizzle’s participation in clinical evaluations with cancer centres across the globe and directly supporting the Company’s licensing partners’ route to market.’

Current stock price: 1.61 pence, up 3.9% on Thursday afternoon in London

12-month change: down 23%

Copyright 2025 Alliance News Ltd. All Rights Reserved.